# Palonosetron

## Aloxi inj 0.25mg/5mL

##### 

| TAH Drug Code      | IALO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Chemotherapy-induced nausea and vomiting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | Chemotherapy-induced nausea and vomiting, associated with emetogenic chemotherapy; Prophylaxis: Adult: 0.25 mg IV over 30 seconds approximately 30 minutes prior to starting chemotherapy. Children and Adolescents (1 month to 17 years old): 20 mcg/kg IV over 15 minutes approximately 30 minutes prior to starting chemotherapy; maximum dose: 1.5 mg.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Hypersensitivity to palonosetron or any component of the formulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adverse Effects    | 1% to 10%: Cardiovascular: Prolonged Q-T interval on ECG (PONV 1% to 5%; chemotherapy-associated <1%), bradycardia (chemotherapy-associated 1%), sinus bradycardia (PONV: 1%), tachycardia (may be nonsustained; 1%), hypotension (<=1%) Central nervous system: Headache (chemotherapy-associated: Adults 9%; infants, children, and adolescents <1%), anxiety (chemotherapy-associated: 1%), dizziness (infants, children, adolescents, and adults ?1%) Dermatologic: Pruritus (PONV: 1%) Endocrine & metabolic: Hyperkalemia (chemotherapy-associated: 1%) Gastrointestinal: Constipation (chemotherapy-associated: 5%), diarrhea (<=1%), flatulence (<=1%) Genitourinary: Urinary retention (<=1%) Hepatic: Increased serum ALT (<=1%; may be transient), increased serum AST (<=1%; may be transient) Neuromuscular & skeletal: Weakness (chemotherapy-associated: 1%) |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

